The BCL11B Knockout DLD-1 Polyclonal Cells represent a CRISPR/Cas9-edited heterogeneous knockout cell population targeting the BCL11B gene in the DLD-1 human colorectal adenocarcinoma epithelial line. This polyclonal design provides a pool of loss-of-function mutants, enabling the study of BCL11B?dependent processes without clonal selection bias. The encoded zinc finger transcription factor regulates T?cell development, neuronal differentiation, and apoptosis, and is considered a tumor suppressor in several malignancies.
The DLD-1 host cell line, a human male colorectal adenocarcinoma model, harbors mutations in APC, KRAS (G13D), TP53 (S241F), and PIK3CA (E545K). These genetic lesions drive constitutive WNT signaling, impaired apoptosis, and altered cell cycle control, recapitulating the molecular pathology of many colorectal cancers. Widely used for cancer biology studies, DLD-1 cells provide a pathologically relevant background for investigating BCL11B function in colorectal tumorigenesis.
BCL11B is a zinc finger transcription factor that interacts with the NuRD complex (HDAC1/2, MTA2), RUNX1, and SIN3A, and is regulated by NOTCH1, ???catenin/TCF, retinoic acid receptors, and TP53. Transcriptionally, it modulates CDKN1A, BAX, BCL2, MYC, and WNT target genes, thereby bridging Notch, WNT, retinoic acid, and DNA damage response cascades. This positions BCL11B as a key node controlling cell fate and survival programs.
Knocking out BCL11B in DLD-1 cells likely disrupts transcriptional regulation of cell cycle and apoptotic pathways. Loss of BCL11B may alter expression of downstream effectors such as MYC and BAX, intensifying WNT/???catenin signaling and compromising DNA damage?induced apoptosis. In the context of co?existing APC, KRAS, TP53, and PIK3CA mutations, this model facilitates dissection of cooperative oncogenic mechanisms and evaluation of BCL11B as a tumor suppressor in colorectal epithelium.
Typical applications include proliferation and colony formation assays, migration/invasion assays, and drug sensitivity screens to assess the impact of BCL11B loss on therapeutic response. Molecular analyses by western blot, RT?qPCR, and RNA?seq enable profiling of downstream targets and signaling changes, while flow cytometry quantifies apoptosis and cell cycle distribution. These tools support drug target identification, mechanistic studies of transcription factor networks, and colorectal cancer research. For further details or to discuss your specific experimental needs, please contact Ascent Research.
